Q1 FY27 earnings call · July 31, 2026

Global Health Ltd (MEDANTA) Q1 FY27 Earnings Call: Plans Rs.4,850 Cr Capex for 2,950 Beds, Guides Earlier Noida EBITDA Breakeven

Cofacto ResearchPublished July 31, 20264 min read
Quick summary

Global Health Ltd held its Q1 FY27 earnings call on July 30, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline Financials & Key Metrics

  • Consolidated income Rs.13,262 Mn — up 26% YoY in Q1 FY 2026-2027, driven by broad-based patient volume growth across the network.
  • EBITDA Rs.3,153 Mn (23.8% margin) — excl. Noida, EBITDA was Rs.3,201 Mn (25.8% margin), reflecting core operating strength before the new unit's drag.
  • PAT Rs.1,573 Mn — compared to Rs.1,590 Mn in Q1 FY 2025-2026, which included a non-recurring exceptional income of Rs.196 Mn (EPCG liability reversal); underlying earnings trend is healthy.
  • IP volumes +28% YoY — OP volumes +34% YoY, occupied bed days +21% YoY; network occupancy at 63% (excl. Noida: 66%).
  • ARPOB Rs.70,244 (+5% YoY) — ARPP (avg. revenue per patient) at Rs.2,01,891, broadly stable YoY; total operational bed capacity reached 7,337 (net +72 beds in Q1).

Margin Dynamics & Growth Drivers

  • Cluster 1 (Gurgaon, Indore, Ranchi) revenue Rs.7,715 Mn — up 10% YoY in Q1 FY 2026-2027, with EBITDA margin expanding to 24.1% (vs. 23.4% YoY) and ARPOB +7% YoY; occupancy 63%.
  • Cluster 2 (Lucknow, Patna, Noida) total income Rs.4,983 Mn — up 55% YoY; excl. Noida, revenue grew 28% and EBITDA +40% YoY, with a margin of 32%.
  • Margin differences are operational, not structural — newer units have lower R&M costs and more efficient manpower structures; corporate overheads are fully loaded into Gurgaon, making cross-cluster comparisons less meaningful.
  • Operating leverage expected at Lucknow and Noida — management sees these units supporting margin stability or improvement as scale builds, though no explicit margin guidance was provided.
  • No structural headwinds to margin expansion cited — management declined to give margin targets but noted only normal cost increases (increments, etc.) as ongoing factors.

Path to EBITDA Breakeven

  • Noida total income Rs.855 Mn — up from Rs.525 Mn in Q4 FY 2025-2026, with EBITDA loss narrowing sharply to Rs.49 Mn from Rs.236 Mn in the prior quarter.
  • Occupancy at 30-40% (misleading due to bed additions) — volumes are growing 30-40% QoQ; beds increased from 320 to 433 with new floors opened.
  • All major specialties operational except liver transplant — high-end equipment (14 OTs, radiation oncology, robot, O-arm) already in place; no OT/ICU capex planned for the next couple of quarters.
  • Management expects EBITDA breakeven earlier than previously expected — period unspecified, but the sharp loss reduction in Q1 FY 2026-2027 supports this trajectory.
  • Cross-network coordination active — patient referrals and senior doctor movement (cardiac surgery, chest surgery) from Gurgaon to Noida help establish departments.

Capacity Growth & Capital Allocation

  • Future capex of Rs.4,850 Cr for 2,950 beds — Rs.1,610 Mn was spent in Q1 FY 2026-2027; total announced pipeline represents nearly 3,350 additional beds (period unspecified for most).
  • Guwahati hospital revised to 650 beds, project cost Rs.9,700 Mn — revised building norms doubled floor plate to ~60,000 sq ft, increased ORs from 13-14 to 28-30, and doubled cath labs/LINACs; no additional land cost.
  • Gorakhpur scaled to 650-bed super specialty hospital — aimed at improving access for patients from the Northeast region; timeline is FY 2027-2028+.
  • Near-term additions: 80 beds in Indore — coming on board by end of Q2/early Q3 FY 2026-2027; Gurgaon adding 44-45 ORs and 2-3 cath labs in Q2 FY 2026-2027.
  • Government's tier 2/3 city policy — management noted the policy is "welcome but not needed for Medanta's Guwahati and Varanasi projects" as approvals are already in place and construction is commencing.

Doctors, Pharmacy & Specialties

  • 70+ doctors onboarded in Q1 FY 2026-2027 — including over 50 senior clinicians across various specialties; senior clinical attrition negligible over the past 6-18 months.
  • Lucknow performed 1,000+ robotic joint replacements — highlighting the ramp-up in high-complexity procedures at cluster 2 facilities.
  • IPD volume growth: cluster 2 hospitals 27%, Lucknow/Patna 20%+ — mature Gurgaon facility grew 7-10%; management cited demand tailwinds from flight to quality care and rising health awareness across central and northern India.
  • Oncology revenue share at 13.5% — down from 14.2% in Q1 FY 2025-2026 due to faster growth in other specialties (e.g., kidney/urology from 7.6% to 8.2%); cancer services overall are growing in absolute terms.
  • Retail pharmacy: 13 stores outside hospitals — management plans steady expansion at 10 per quarter, potentially increasing to 15-20 over the next 2-3 years (FY 2027-2028 to FY 2028-2029), focused on UP and Bihar.
  • International patient revenue Rs.782 Mn (+23% YoY) — OPD pharmacy revenue Rs.609 Mn (+51% YoY); the "CGHS rate hike announced in October 2025 was fully captured in Q1 FY 2026-2027" but did not move the needle as CGHS comprises only ~10-12% of revenue.
  • Nursing and junior doctor attrition is industry-wide — management described "high attrition in nursing and junior doctors is industry-wide with no significant change" in recent periods.

Ask about this

Ask Cofacto a question about this call. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This earnings call summary is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.